Smoking and Psoriasis: What the Research Actually Shows

Smoking is one of the most consistently documented environmental risk factors in all of psoriasis research. Unlike some proposed triggers with thin or conflicting evidence, the smoking-psoriasis link has been studied across millions of participants, and the pattern holds up remarkably well.

This guide walks through what the strongest current research actually shows: how much smoking raises risk, the biology behind that risk, its surprising relationship with psoriatic arthritis, its unusually strong link to one specific psoriasis subtype, and what happens when people quit.

How Strong Is the Smoking-Psoriasis Link?

Smoking’s connection to psoriasis isn’t based on a single study or a handful of small trials. It’s one of the most extensively replicated findings in psoriasis epidemiology.

What the Largest Analysis to Date Shows

A comprehensive 2026 dose-response meta-analysis offers the clearest current picture available. Drawing on 30 observational studies involving more than 25 million participants, smoking was associated with a summary relative risk of 1.67 for developing psoriasis, and the relationship showed a clear, positive dose-response pattern meaning heavier smoking was linked to progressively higher risk.

This dose-response finding matters because it strengthens the case for a genuine causal relationship rather than mere correlation. When risk rises in step with exposure amount, in a graded, predictable way, that pattern is far more convincing than a simple yes-or-no association.

Former Smokers Aren’t Fully in the Clear Either

One of the more sobering findings from this same analysis concerns people who’ve already quit. Former smokers also remained at higher risk than never-smokers, even after stopping.

This doesn’t mean quitting is pointless, a point covered in detail later in this guide. It does mean smoking’s effects on psoriasis risk appear to linger for some time even after cessation, rather than reversing immediately.

The Biology: How Smoking Actually Triggers Psoriasis

Understanding why smoking raises psoriasis risk requires looking at several overlapping biological mechanisms. Tobacco smoke doesn’t affect the skin through just one pathway; it appears to interact with nearly every part of the inflammatory process described in our “Inflammation and Psoriasis” guide.

Oxidative Stress and Inflammatory Signaling

Tobacco smoke floods the body with harmful free radicals, setting off a cascade of downstream immune activation. Smoking initially produces deleterious free radicals, leading to intracellular signaling involving mitogen-activated protein kinase, activator protein 1, nuclear factor kappa B, and Janus kinase signal transducers and activators of transcription, all of which are central to how psoriatic inflammation unfolds.

This signaling cascade doesn’t stay contained; it actively recruits and activates the same immune cells implicated throughout our pillar guide’s discussion of psoriasis pathogenesis. Active immune cells and keratinocytes trigger increased secretion of inflammatory cytokines such as TNF-alpha and interferon-gamma, which in turn exacerbate psoriasis.

Nicotine’s Direct Effect on Immune Cells

Nicotine itself, separate from the broader chemical cocktail in tobacco smoke, appears to have specific, targeted effects on immune signaling relevant to psoriasis. Nicotine can stimulate the production of IL-12 by dendritic cells and increase the expression of CD40 and CD86, thereby stimulating T-cell activation, a pathway that sits close to the core immune mechanisms discussed in our “What Causes Psoriasis?” guide.

Nicotine also acts through a different route entirely, via receptors normally involved in the nervous system. There are acetylcholine receptors all over the body, including in skin cells and inflammatory cells, and research published in the journal Tobacco Control found that nicotine compromises the immunity of skin cells, making an inflammatory response, including the red, raised plaques of psoriasis, considerably more likely.

Abnormal Blood Vessel Growth

Beyond immune signaling, smoking appears to directly affect the blood vessel changes that contribute to visible psoriasis plaques. Nicotine induces overexpression of vascular endothelial growth factor, worsening the pathological blood vessel growth already seen in patients with psoriasis, reinforcing the redness and inflammation characteristic of active plaques.

Genetic Interactions

Smoking’s effects don’t appear uniform across all patients; genetics may shape how much impact it has on any individual’s risk. Smoking has been reported to worsen psoriasis in several ways, including through interactions with genetic susceptibility loci such as the HLA-Cw6 allele, the same gene variant discussed in our “What Causes Psoriasis?” guide as being linked to earlier-onset disease.

Dioxins and Non-Nicotine Tobacco Components

It’s worth noting that nicotine isn’t the only relevant chemical in tobacco smoke. Dioxins produced by tobacco burning can bind to aromatic hydrocarbon receptors, adding yet another distinct biological pathway through which smoking may influence psoriasis risk beyond nicotine alone.

This distinction matters for an important, emerging research question: is nicotine itself the primary driver, or is it the thousands of other compounds in burned tobacco? A 2026 genetic study specifically designed to answer this question is discussed later in this guide.

Palmoplantar Pustulosis: The Strongest Smoking Link in All of Dermatology

If there’s one psoriasis-related condition where the smoking connection is almost impossible to overstate, it’s palmoplantar pustulosis (PPP), a condition covered briefly in our types-of-psoriasis guide. The strength of this specific association is genuinely remarkable by dermatology research standards.

Just How Strong Is This Link?

The numbers here are striking even compared to other well-established smoking-disease relationships. Palmoplantar pustulosis is closely associated with smoking; 95% of patients are smokers at the onset of the disease, according to research published in the Journal of the American Academy of Dermatology.

The risk increase for women specifically is extraordinary. Among the roughly 90% of PPP patients who are women, the risk that a woman who smokes will develop PPP is 74 times higher than the risk for a nonsmoking woman of the same age. Few environmental exposures in all of dermatology carry a relative risk this large.

Why the Palms and Soles Specifically?

The localization of PPP to the palms and soles isn’t arbitrary; it appears to relate directly to how nicotine moves through the body. Nicotine is excreted through the eccrine palmar sweat duct, which is precisely the structure targeted by the inflammation in PPP. Nicotinic receptors have also been specifically identified in the skin of PPP patients, providing a direct anatomical explanation for why this particular smoking-related condition concentrates exactly where it does.

The Immune Mechanism Behind PPP

Recent laboratory research has identified a specific pathway connecting cigarette smoke to PPP’s characteristic pustules, and it involves an unexpected starting point: the tonsils. A strong association between PPP and tobacco smoking has been reported, and it has been speculated that the IL-17A pathway plays an important role in the condition.

Laboratory experiments have traced this connection in detail. Researchers investigated cigarette smoke’s role in PPP pathogenesis through an IL-17A-induced production of IL-36 gamma in tonsillar epithelial cells, suggesting cigarette smoke exposure at the tonsils may trigger a cytokine cascade that ultimately manifests as pustules on the hands and feet, a genuinely unexpected anatomical pathway.

Is PPP Even the Same Disease as Psoriasis?

This is a genuinely important, evolving question in dermatology, and it’s worth addressing honestly. Originally thought to be palmoplantar psoriasis, recent studies have presented evidence that PPP may be an entirely separate disease, based on its unique characteristics and non-response to common psoriatic treatments.

Supporting this reclassification, genetic research has identified a distinct pattern for PPP compared to plaque psoriasis. A genome-wide meta-analysis of palmoplantar pustulosis implicated Th2 immune responses and cigarette smoking specifically in the disease’s pathogenesis, a somewhat different immune signature than the Th17-dominant pattern typically seen in plaque psoriasis, as described in our pillar guide’s etiopathogenesis section.

Regardless of how this classification question is ultimately settled, the clinical message for patients remains the same: PPP is one of the clearest examples anywhere in dermatology of a condition where smoking cessation genuinely, measurably changes disease course.

The Psoriatic Arthritis Paradox

This is one of the more genuinely surprising findings in recent psoriasis research, and it deserves to be presented with real nuance rather than oversimplified. It does not, in any way, suggest smoking is protective or advisable.

A Counterintuitive Finding

While smoking clearly raises the risk of developing psoriasis itself, its relationship with psoriatic arthritis appears to run in the opposite direction among people who already have psoriasis. While smoking is known to increase the risk of developing psoriasis in the general population, recent studies indicate that it may, paradoxically, reduce the likelihood of developing psoriatic arthritis among those affected by psoriasis.

Why This Isn’t a Reason to Smoke

This finding sits alongside a large body of research showing smoking dramatically worsens nearly every other aspect of psoriatic disease, including overall severity, treatment response (discussed in detail below), and general health risks entirely unrelated to psoriasis, from cardiovascular disease to cancer. A modest, inconsistently replicated reduction in one specific downstream complication doesn’t come close to offsetting these much larger, well-established harms.

This pattern actually has a notable precedent in a closely related disease. Smoking is a well-established risk factor for rheumatoid arthritis, with risk roughly doubling among heavier smokers, showing that smoking’s relationship with different inflammatory joint conditions isn’t uniform, and that isolated paradoxical findings shouldn’t be read as a general health signal in either direction.

The Honest Scientific Takeaway

Researchers studying this paradox aren’t suggesting patients weigh it as a genuine trade-off. Rather, findings like this help scientists understand the underlying biology more precisely, since a factor that raises risk for one related condition while appearing to lower risk for another offers real clues about how these two diseases, despite sharing an underlying inflammatory foundation, may diverge biologically in specific ways.

Disentangling Nicotine From the Rest of Tobacco Smoke

A sophisticated 2026 genetic study has begun to answer a question that’s been difficult to resolve through observational research alone: is nicotine itself the main driver of psoriasis risk, or is it the thousands of other chemicals in burned tobacco?

A Novel Research Approach

Researchers used a genetic technique that can separate the effects of different exposures that normally occur together in real smokers. This study applied multivariable Mendelian randomization, jointly modeling genetically proxied nicotine metabolite ratio and cigarettes-per-day intensity, to estimate their independent effects on liability to psoriasis and psoriatic arthritis, using chronic obstructive pulmonary disease as a positive control.

This approach matters because real-world smokers can’t be neatly divided into “nicotine-only” and “everything-else-only” groups; every cigarette delivers both simultaneously. Genetic methods like this one offer a way to statistically tease apart which component is actually doing the damage, at least at the population level, without needing an impossible real-world experiment.

Why This Research Direction Matters

If future findings from this line of research confirm that non-nicotine components of tobacco smoke are the primary driver of psoriasis risk, it could have real implications for harm-reduction conversations, including around nicotine replacement therapy and reduced-harm nicotine products, during smoking cessation. This remains an active, evolving area of research rather than a settled question, and specific conclusions from this study were still emerging at the time of writing.

How Smoking Affects Psoriasis Treatment Response

Beyond raising the initial risk of developing psoriasis, smoking appears to genuinely interfere with how well standard treatments work once someone already has the condition. This is a critically important, if underdiscussed, piece of the smoking-psoriasis relationship.

Reduced Response to Biologic Therapy

Research specifically examining treatment outcomes has found a clear, statistically significant pattern. A meta-analysis found that smoking increases psoriasis risk and negatively impacts the benefits of biologic agents, the very medications discussed in depth in our pillar guide’s treatment section.

A separate prospective study quantified this effect in more concrete terms. Current smokers showed a significantly weaker likelihood of achieving a 75% improvement in PASI score after eight weeks of treatment compared with non-smokers, while former smokers showed a meaningfully weaker association than current smokers, suggesting a graded relationship between smoking status and treatment success.

Quitting Improves Treatment Outcomes, Even Mid-Treatment

This is genuinely encouraging news buried within an otherwise sobering set of findings. Among psoriasis patients who smoked, former smokers had meaningfully higher PASI75 achievement at week 8 than current smokers, even after adjusting for potential confounding factors.

This finding has direct, practical relevance for anyone currently on psoriasis treatment. It suggests quitting isn’t just a long-term risk-reduction strategy; it may meaningfully improve how well an active treatment plan works right now, tying directly into the treat-to-target framework discussed in our “Creating Treatment Goals” guide.

Why This Matters for Clinical Care

Given this evidence, researchers studying this relationship have drawn a clear practical conclusion. Implementing tobacco control measures among patients with psoriasis is beneficial for improving treatment response, according to the study’s authors.

This is worth raising directly with your dermatologist if you smoke and are starting or adjusting biologic therapy. Smoking status is exactly the kind of modifiable factor that deserves a place in treatment planning conversations, alongside the medication choice itself.

What Happens When You Quit

Given how consistently smoking is linked to both psoriasis risk and treatment resistance, a natural question follows: does quitting actually help, and how much?

Quitting Reduces the Risk of Developing Psoriasis

A large-scale South Korean cohort study offers some of the best available evidence on this question, tracking millions of people over nearly two decades. Compared with continuous smoking, smoking cessation was associated with a decreased risk of developing psoriasis, and this risk-reducing effect was more pronounced in those who maintained a smoke-free status over time.

The scale of this study lends real weight to its findings. Using a cohort of over 5.7 million participants without psoriasis at baseline, followed from 2004 through 2021, researchers found that compared with sustained smokers, smoking quitters showed a reduced risk of developing psoriasis, with an adjusted hazard ratio of 0.91.

This same research found the benefit was particularly clear for specific subtypes. Smoking quitters had a lower risk of developing psoriasis, especially plaque psoriasis and palmoplantar pustulosis specifically, compared with those who continued smoking throughout the study period.

The Dramatic Effect on Existing Palmoplantar Pustulosis

For patients who already have PPP, the smoking-specific research described earlier in this guide translates into one of the more striking cessation-response stories in all of dermatology. The positive benefit of smoking cessation is much more significant in reducing PPP than in reducing general psoriasis risk, aligning with the theory that nicotine acts as a genuinely causative agent in this specific condition.

Case-based clinical reports have documented this effect directly and rapidly. One report specifically titled its findings around the speed of improvement, describing rapid improvement of palmoplantar disease following smoking cessation, a pattern consistent with the direct nicotine-receptor mechanism described earlier in this guide.

Why the Benefit Isn’t Always Immediate

It’s worth being honest that quitting isn’t necessarily an overnight fix, particularly for plaque psoriasis rather than PPP specifically. As noted earlier, former smokers in the largest dose-response analysis available still carried somewhat elevated risk compared to people who never smoked, suggesting some biological effects of smoking may persist for a meaningful period after cessation.

This doesn’t diminish the value of quitting; every piece of evidence in this guide points toward quitting being clearly beneficial, both for psoriasis specifically and for overall health. It simply means realistic expectations matter here just as they do throughout psoriasis treatment generally, echoing the honest, evidence-based framing emphasized throughout our pillar guide.

Secondhand Smoke and Psoriasis

Most research in this area focuses on active, personal smoking, but it’s a reasonable question whether secondhand exposure carries similar risk. This remains a less thoroughly studied area than direct smoking, and the evidence base is comparatively thinner.

Given the biological mechanisms described throughout this guide, particularly the oxidative stress and immune-activation pathways that don’t require inhaling smoke directly to be triggered, there’s a plausible biological basis for secondhand smoke contributing to risk as well. Until more direct research specifically quantifies this relationship, the most responsible takeaway is that reducing secondhand smoke exposure, particularly for household members already living with psoriasis, is a reasonable, low-risk precaution grounded in the same biological logic covered throughout this guide.

Practical Guidance for Patients

Bringing together everything covered in this guide, a few clear, evidence-based conclusions stand out for anyone with psoriasis who currently smokes, or who is deciding whether smoking status matters for their care.

Smoking status is worth discussing openly with your dermatologist. Given its documented effect on both disease risk and treatment response, this is a legitimate, clinically relevant topic for a psoriasis appointment, not a separate, unrelated health conversation.

If you’re starting biologic therapy, quitting beforehand may improve your odds of success. The treatment-response research discussed above suggests this isn’t just a general health recommendation; it’s specifically relevant to how well your prescribed medication is likely to work.

If you have palmoplantar pustulosis, smoking cessation deserves particular priority. Given the exceptionally strong association and documented rapid improvement after quitting described in this guide, this is one of the clearest, most actionable pieces of psoriasis-related lifestyle guidance available anywhere in the field.

Don’t be discouraged if improvement isn’t instant after quitting. As discussed above, some elevated risk may persist for a period even after cessation, particularly for plaque psoriasis, so patience alongside continued adherence to your broader treatment plan remains important.

Ask about cessation support resources. Given how consistently the research supports quitting’s benefit, many dermatology practices can point patients toward smoking cessation programs, nicotine replacement options, or referrals better suited to supporting a successful quit attempt than willpower alone. (For a full walkthrough of proven psoriasis treatment options, see our complete guide, “What Is Psoriasis? A Complete Guide to Causes, Symptoms, and Treatment.”)

---

Frequently Asked Questions

1. Does smoking actually cause psoriasis?

Smoking is strongly and consistently associated with increased psoriasis risk across dozens of large studies, with a clear dose-response relationship that supports a genuine causal role rather than simple correlation. As with most chronic diseases, it’s best understood as a major contributing risk factor rather than the sole cause.

2. How much does smoking increase psoriasis risk?

A large 2026 meta-analysis covering more than 25 million participants found smokers had roughly 67% higher risk of developing psoriasis compared to non-smokers, with risk increasing further at higher smoking levels. This makes smoking one of the more significant, modifiable risk factors identified in psoriasis research.

3. Is the smoking-psoriasis link the same for everyone?

No. The connection appears strongest for palmoplantar pustulosis, where the association is dramatically higher than for plaque psoriasis, and genetic factors like the HLA-Cw6 gene variant may also influence how much smoking affects individual risk.

4. Does quitting smoking improve existing psoriasis?

Yes, based on multiple large studies, though the degree and speed of improvement vary by subtype. Palmoplantar pustulosis often shows notably rapid, significant improvement after cessation, while plaque psoriasis risk reduction tends to build more gradually over time.

5. Can smoking make my psoriasis medication less effective?

Yes. Research shows current smokers are significantly less likely to achieve strong treatment responses to biologic therapy compared to non-smokers, while former smokers show meaningfully better outcomes than current smokers.

6. Why does smoking sometimes seem linked to lower psoriatic arthritis risk?

Some research has found this counterintuitive pattern, but it shouldn’t be interpreted as a reason to smoke. Smoking clearly worsens psoriasis severity, treatment response, and overall health risk in numerous other well-documented ways that far outweigh this isolated, still-developing finding.

7. Does secondhand smoke affect psoriasis risk?

This hasn’t been as thoroughly studied as direct smoking, but the underlying biological mechanisms involved don’t necessarily require direct inhalation to be triggered. Reducing secondhand smoke exposure is a reasonable precaution, particularly for household members with existing psoriasis.

8. Is nicotine or something else in cigarettes responsible for the psoriasis link?

This is an active area of research, and newer genetic studies are specifically working to separate nicotine’s effects from those of the thousands of other chemicals in tobacco smoke. Current evidence suggests both nicotine-specific and broader tobacco-smoke pathways likely contribute.

9. How long after quitting does psoriasis risk return to normal?

Available research suggests some elevated risk can persist in former smokers compared to people who never smoked, though the degree diminishes over time, particularly with sustained smoke-free status. This varies by psoriasis subtype, with palmoplantar pustulosis generally showing faster, more dramatic improvement than plaque psoriasis.

10. Should I quit smoking before starting a biologic for psoriasis?

Given the documented link between current smoking and reduced biologic treatment response, discussing cessation with your dermatologist before or during biologic therapy is a reasonable, evidence-supported step. This is worth raising directly as part of your treatment planning conversation.

Sources and References

1. “Smoking, Alcohol Consumption, and Psoriasis Risk: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies,” Frontiers in Public Health, 2026.
2. “The Impact of Smoking on Prevalence of Psoriasis and Psoriatic Arthritis,” Pharmaceutics, 2025.
3. “Impact of Smoking on Psoriasis Risk and Treatment Efficacy: A Meta-Analysis,” Journal of International Medical Research, SAGE Journals, 2020.
4. “Disentangling Nicotine vs Non-Nicotine Components of Tobacco Exposure in Psoriasis and Psoriatic Arthritis: A Multivariable and Trans-Ethnic Mendelian Randomization Study,” Clinical, Cosmetic and Investigational Dermatology, Taylor & Francis, 2026.
5. HealthCentral, “How Does Smoking Affect Psoriasis?”
6. Naldi L., “Psoriasis and Smoking: Links and Risks,” Psoriasis: Targets and Therapy, Dove Medical Press, 2016.
7. “Cigarette Smoking and Risk of Rheumatoid Arthritis: A Dose-Response Meta-Analysis,” PMC.
8. “Tobacco Smoking Negatively Influences the Achievement of Greater Than Three-Quarters Reduction in Psoriasis Area and Severity Index After Eight Weeks of Treatment Among Patients With Psoriasis,” Tobacco Induced Diseases, 2024.
9. “Smoking, Palmoplantar Pustulosis & Psoriasis,” Foot Expert (Dr. C. O’Doherty), 2024.
10. “The Psoriasis Variant Palmoplantar Pustulosis Can Be Improved After Cessation of Smoking,” Journal of the American Academy of Dermatology, 2006.
11. Kobayashi K. et al., “Cigarette Smoke Underlies the Pathogenesis of Palmoplantar Pustulosis via an IL-17A-Induced Production of IL-36γ in Tonsillar Epithelial Cells,” Journal of Investigative Dermatology, PubMed and ScienceDirect, 2021.
12. Kim S.R., Choi Y-G., Jo S.J., “Effect of Smoking Cessation on Psoriasis Vulgaris, Palmoplantar Pustulosis and Generalized Pustular Psoriasis,” British Journal of Dermatology, Oxford Academic and PubMed, 2024.
13. “Rapid Improvement of Palmoplantar Psoriasis After Cessation of Smoking,” PMC.
14. “A Genome-Wide Meta-Analysis of Palmoplantar Pustulosis Implicates TH2 Responses and Cigarette Smoking in Disease Pathogenesis,” Journal of Allergy and Clinical Immunology, 2024.
15. Pezzolo E., Naldi L., “The Relationship Between Smoking, Psoriasis and Psoriatic Arthritis,” Expert Review of Clinical Immunology, 2019.

This article is intended for general educational purposes and does not replace personalized medical advice. Anyone who smokes and has psoriasis should discuss cessation strategies and their potential treatment benefits with their dermatologist or primary care physician.